These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22628357)

  • 1. The large sample bounds on the principal strata effect with application to a prostate cancer prevention trial.
    Chiba Y
    Int J Biostat; 2012 May; 8(1):Article 12. PubMed ID: 22628357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of the Prostate Cancer Prevention Trial (PCPT).
    Goodman PJ; Tangen CM; Crowley JJ; Carlin SM; Ryan A; Coltman CA; Ford LG; Thompson IM
    Control Clin Trials; 2004 Apr; 25(2):203-22. PubMed ID: 15020037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
    Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
    J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited.
    Klein EA; Tangen CM; Goodman PJ; Lippman SM; Thompson IM
    J Clin Oncol; 2005 Oct; 23(30):7460-6. PubMed ID: 16157937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Instruments and bounds for causal effects under the monotonic selection assumption.
    Taguri M; Chiba Y
    Int J Biostat; 2012 Aug; 8(1):24. PubMed ID: 22944723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bounds on causal effects in randomized trials with noncompliance under monotonicity assumptions about covariates.
    Chiba Y
    Stat Med; 2009 Nov; 28(26):3249-59. PubMed ID: 19777494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
    Lotan Y; Cadeddu JA; Lee JJ; Roehrborn CG; Lippman SM
    J Clin Oncol; 2005 Mar; 23(9):1911-20. PubMed ID: 15774783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The benefit of stratification in clinical trials revisited.
    Ganju J; Zhou K
    Stat Med; 2011 Oct; 30(24):2881-9. PubMed ID: 21905064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Test homogeneity of odds ratio in a randomized clinical trial with noncompliance.
    Lui KJ; Chang KC
    J Biopharm Stat; 2009 Sep; 19(5):916-32. PubMed ID: 20183452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated impact of the Prostate Cancer Prevention Trial on population mortality.
    Unger JM; Thompson IM; LeBlanc M; Crowley JJ; Goodman PJ; Ford LG; Coltman CA
    Cancer; 2005 Apr; 103(7):1375-80. PubMed ID: 15739207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bounds on potential risks and causal risk differences under assumptions about confounding parameters.
    Chiba Y; Sato T; Greenland S
    Stat Med; 2007 Dec; 26(28):5125-35. PubMed ID: 17525935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for prostate cancer: opportunities for prevention.
    Thompson IM; Coltman CA
    Semin Urol Oncol; 1996 May; 14(2 Suppl 2):4-10; discussion 10-1. PubMed ID: 8725886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
    Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-grade prostate cancer and finasteride.
    Lebdai S; Bigot P; Azzouzi AR
    BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The PCPT trial].
    Hamdy FC; Rouprêt M
    Prog Urol; 2008 Apr; 18 Suppl 3():S40-3. PubMed ID: 18455082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention of prostate cancer with finasteride.
    Thompson I; Feigl P; Coltman C
    Important Adv Oncol; 1995; ():57-76. PubMed ID: 7672814
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate cancer: a serious disease suitable for prevention.
    Fitzpatrick JM; Schulman C; Zlotta AR; Schröder FH
    BJU Int; 2009 Apr; 103(7):864-70. PubMed ID: 19302133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.
    Shepherd BE; Gilbert PB; Jemiai Y; Rotnitzky A
    Biometrics; 2006 Jun; 62(2):332-42. PubMed ID: 16918897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large sample bounds on the survivor average causal effect in the presence of a binary covariate with conditionally ignorable treatment assignment.
    Freiman MH; Small DS
    Int J Biostat; 2014; 10(2):143-63. PubMed ID: 25294716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer.
    Zeliadt SB; Etzioni RD; Penson DF; Thompson IM; Ramsey SD
    Am J Med; 2005 Aug; 118(8):850-7. PubMed ID: 16084177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.